# Xeris Biopharma Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/XERS/xeris-biopharma-reports-first-quarter-2026-financial-results
Ticker: XERS
Company: Xeris Pharmaceuticals
Source: Xeris Pharmaceuticals
Published: 2026-05-07 11:00 EST
Original Source URL: https://xerispharma.com
## Summary

Total product revenue increased 43% year-over-year to over $82 million Recorlev net revenue increased 95% year-over-year to $50 million Tightens full-year 2026 total revenue guidance to $380 million to $390 million Hosts conference call and webcast today at 8:30 a.m.

## Article Body
Total product revenue increased 43% year-over-year to over $82 million Recorlev net revenue increased 95% year-over-year to $50 million Tightens full-year 2026 total revenue guidance to $380 million to $390 million Hosts conference call and webcast today at 8:30 a.m.
## Recent Company News
- 2026-05-07 11:00 EST — [Xeris Biopharma Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/XERS/xeris-biopharma-reports-first-quarter-2026-financial-results) — Source: Xeris Pharmaceuticals
- 2026-04-23 11:30 EST — [Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026](https://biopharmsignal.com/news/XERS/xeris-biopharma-to-report-first-quarter-2026-financial-results-on-may-7-2026) — Source: Xeris Pharmaceuticals
- 2026-04-03 20:15 EST — [Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/XERS/xeris-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4) — Source: Xeris Pharmaceuticals
- 2026-03-02 12:00 EST — [Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance](https://biopharmsignal.com/news/XERS/xeris-biopharma-reports-record-performance-for-fourth-quarter-and-full-year-2025-and-provides-full-year-2026-guidance) — Source: Xeris Pharmaceuticals
- 2026-02-26 22:55 EST — [Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit](https://biopharmsignal.com/news/XERS/xeris-biopharma-subsidiaries-file-recorlevr-patent-infringement-lawsuit) — Source: Xeris Pharmaceuticals
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)